Showing 2331-2340 of 3017 results for "".
- FDA Follow-Up Study: Sunscreen Active Ingredients Are Absorbed by Bloodstreamhttps://practicaldermatology.com/news/fda-follow-up-study-sunscreen-active-ingredients-are-absorbed-by-bloodstream/2460258/Six active ingredients administered in four different sunscreen formulations are systemically absorbed, according to a new report. The study was sponsored by U.S. Food and Drug Administration (FDA) and is a follow-up to a May 2019 study that generated a lot of headlines. The new report
- Revance Acquires Exclusive US Distribution Rights to Teoxane SA Fillershttps://practicaldermatology.com/news/revance-acquires-exclusive-us-distribution-rights-to-teoxane-sa-fillers-1/2460250/Revance Therapeutics, Inc. is the exclusive commercialization partner of Teoxane SA in the US. With a new distribution agreement just announced, Revance gains immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (RHA®) line of fillers in the
- DermWire Exclusive: Meet Allē, Allergan’s Upgraded Patient Loyalty Programhttps://practicaldermatology.com/news/dermwire-exclusive-meet-alle-allergans-upgraded-patient-loyalty-program/2460244/Allergan’s Brilliant Distinctions customer loyalty program is getting a facelift in honor of its 2nd decade. The program is smarter, faster and now goes by Allē. It’s much more than a new name, shares Carrie Strom, Allergan’s Senior Vice President o
- DermTech’s Pigmented Lesion Assay Receives Medicare Coveragehttps://practicaldermatology.com/news/dermtechs-pigmented-lesion-assay-receives-medicare-coverage/2460241/The Medicare Administrative Contractor Palmetto GBA MolDx issued a final local coverage determination for DermTech, Inc.'s Pigmented Lesion Assay (PLA). The PLA test is used to help rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more cli
- BTL Files Patent Infringement Lawsuit Against Allergan and Zimmer Related to Emsculpthttps://practicaldermatology.com/news/btl-files-patent-infringement-lawsuit-against-allergan-and-zimmer-related-to-emsculpt-1/2460239/BTL Aesthetics' US affiliate has filed a lawsuit against Allergan plc, Ireland and its affiliates, and Zimmer MedizinSysteme GmbH, Germany, and its affiliate, in the US Federal District Court for the District of Delaware. The lawsuit asserts
- Ortho Dermatologics Expands Solta Medical Team with New Hireshttps://practicaldermatology.com/news/ortho-dermatologics-expands-solta-medical-team-with-new-hires/2460237/Ortho Dermatologics is staffing up its Solta Medical business unit. The new appointments include the following: Liz Newman, General Manager, Solta, North America Newman first joined Solta in January 2018 as se
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres
- Keloid Breakthrough: Mount Sinai Researchers Show Keloid Shrinkage with Dupilumabhttps://practicaldermatology.com/news/keloid-breakthrough-mount-sinai-researchers-show-keloid-shrinkage-with-dupilumab/2460223/Keloid lesions exhibit increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy, Mount Sinai researchers report. Researchers, led by Emma Guttman-Yassky, MD, PhD, Vice Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York,
- Melanoma Rates Drop Sharply Among Teens, Young Adultshttps://practicaldermatology.com/news/melanoma-rates-drop-sharply-among-teens-young-adults/2460217/Cases of melanoma among U.S. adolescents and young adults declined markedly from 2006 to 2015 - even as the skin cancer's incidence continued to increase among older adults and the general population during the span, new research in JAMA Dermatology shows. The finding,
- Allergan Pays Exicure $25M upfront in Collaboration Deal to Develop Hair Loss Treatmenthttps://practicaldermatology.com/news/allergan-pays-exicure-25m-upfront-in-collaboration-deal-to-develop-hair-loss-treatment/2460216/Allergan Pharmaceuticals International Limited has entered into a global collaboration agreement with Exicure to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to licen